CytRx Corporation

Use of breakthrough target demonstrated to regulate obesity licensed

Published in Biotech Law Weekly, June 18th, 2004

CytRx Corporation (CYTRE) has entered into a license agreement with Imperial College Innovations Limited, the technology transfer company of Imperial College London, for exclusive rights to Imperial's intellectual property covering a drug screening method using Rip140, a nuclear hormone co-repressor that regulates fat accumulation.

This proprietary technology is covered by a pending patent application filed by the licenser. Imperial College Innovations will receive a license fee, milestone payments, and royalties on net sales of any resulting products.

In experiments conducted by professor Malcolm G. Parker, PhD, of Imperial College London, when this...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Law Weekly

Source: Biotech Law Weekly (2004-06-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry